Deborah Dunsire, M.D., is the CEO of FORUM Pharmaceuticals Inc., a Massachusetts-based firm that focuses on development of new medicines for people with serious brain diseases, including schizophrenia and Alzheimer's disease. She brings more than 25 years of scientific, clinical, operational and commercial experience, and proven leadership in the biological and pharmaceutical industry. Prior to joining FORUM in 2013, she was previously the president and chief executive of Millennium Pharmaceuticals, Inc. (now Millennium: The Takeda Oncology Company) from 2005 to 2013. She transformed Millennium into a biotechnology industry leader by focusing R&D, driving the development pipeline, fostering a culture of employee engagement and increasing the commercial mindset across the organization to enhance the commercial success of marketed products. The company was acquired by Takeda Pharmaceutical Company Limited in 2008 for $8.8–one of the largest biotech acquisitions at the time. Prior to leading Millennium, Dr. Dunsire led Novartis Oncology U.S., playing a critical role in the broad development and successful launch of a number. Over 10 years, she increased the North American Oncology revenue from $50 million to more than $2.2 billion. She served on the U.S. Pharmaceutical Executive Committee at Novartis.
Dr. Dunsire serves on the boards of Allergen, Inc., the Biotechnology Industry Organization (BIO), Museum of Science (Boston), Massachusetts General Hospital Research Advisory Council, CancerCare (New York) and Gabrielle's Angels Foundation for Cancer Research. She has received numerous awards, including the 2001 American Cancer Society Excalibur Award, the 2009 Healthcare Businesswomen's Association's "Woman of the Year," the 2011 MassBio Innovator Award and 2013 Boston CEO Conference Lifetime Achievement Award. She received her medical degree from the University of Witwatersand, Johannesburg, South Africa.
Charles Pepin is lead portfolio manager of the T. Rowe Price Distribution Management Service, which optimizes capital appreciation for institutional clients through the analysis, retention, and informed sale of shares distributed from private equity partnerships. Mr. Pepin is a vice president of T. Rowe Price Group, Inc. he is a member of investment Advisory Committees for the U.S. Structured Research Equity and Health Sciences Equity Strategies. Mr. Pepin has 21 years of investment experience, 19 of which have been with T. Rowe Price. He joined the firm in 1994 as an equity research analyst following health care services and consumer companies. He also served as a director of Equity Research, North America from 2005 to 2013. Prior to joining the firm, Mr. Pepin was an investment banking analyst at Piper Jaffray, Inc.
Mr. Pepin earned a B.A., magna cum laude, in economics from Colby College and an M.B.A. from the Tuck School of Business at Dartmouth College and as a member of Phi Beta Kappa. He serves on board of River Valley Ranch, a Christian camp ministry in Maryland. Mr. Pepin lives in Baltimore County with his Wife, Ellen (Gordon ’90).